Last10K.com

Brainstorm Cell Therapeutics Inc (BCLI) SEC Filing 10-K Annual report for the fiscal year ending Wednesday, December 31, 2008

Brainstorm Cell Therapeutics Inc.

CIK: 1137883 Ticker: BCLI

View differences made from one year to another to evaluate Brainstorm Cell Therapeutics Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Brainstorm Cell Therapeutics Inc..

Continue

Assess how Brainstorm Cell Therapeutics Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Brainstorm Cell Therapeutics Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2009 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools
Ticker: BCLI
CIK: 1137883
Form Type: 10-K Annual Report
Accession Number: 0001144204-09-020677
Submitted to the SEC: Wed Apr 15 2009 3:10:43 PM EST
Accepted by the SEC: Wed Apr 15 2009
Period: Wednesday, December 31, 2008
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/bcli/0001144204-09-020677.htm